11/03/2025 13:30
IAMPHENOM Europe Conference Focusing on Applied AI Is Sold Out

Phenom, the leader in applied AI that helps organisations hire faster, develop better and retain longer, announced its first IAMPHENOM Europe conference — the only applied AI event for human resources in the region — is sold out. A waitlist is available on a first-come, first-serve basis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251103977081/en/Phenom announced its first IAMPHENOM Europe conference — the only applied AI event ...

12/02/2025 13:00
Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies

Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced initial clinical results from 1st two cohorts of its ongoing Phase 1 clinical trial evaluating AUR112 in patients with relapsed or refractory lymphoid malignancies. Early findings show that AUR112 is safe, well tolerated, demonstrating meaningful clinical activity, with objective responses observed across multiple lymphoma subtypes, including Mantle Cell Lymphoma (MCL) a...

12/02/2025 13:00
Luma AI Opens for International Business With Former WPP Executive Jason Day Leading New London Office

Luma AI, the frontier artificial intelligence company building multimodal AGI intelligence and known for its flagship product Dream Machine, today announced a major step in its global expansion with the opening of its first international office in London, UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202217704/en/LUMA AI OPENS FOR INTERNATIONAL BUSINESS WITH FORMER WPP EXECUTIVE JASON DAY LEADING NEW LONDON OFFICE As creative...

12/02/2025 13:00
AdvanCell Initiates Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer

AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the initiation of the TheraPb Phase 2 expansion trial (NCT05720130) evaluating its lead investigational candidate, ADVC001, in metastatic prostate cancer. The news follows the encouraging Phase 1b dose escalation results presented at the European Society for Medical Oncology (ESMO) 2025 congress that showed a favorable safety profile and compelling anti-tumor activi...

AFP photojournalist Ina Fassbender awarded first prize in the 2024 VDS Sports Photo Competition

Ina Fassbender secured first place for her photograph ‘Looking Forward to Euro’, taken in Essen during the 2024 UEFA European football championship.

Ina Fassbender secured first place for her photograph ‘Looking Forward to Euro’, taken in Essen during the 2024 UEFA European football championship.

Phil Chetwynd on France 24: AI and the Future of Journalism

AFP’s Global News Director, Phil Chetwynd, appeared on France 24’s Scoop on Friday, 7 February, to discuss artificial intelligence and its impact on journalism.

AFP’s Global News Director, Phil Chetwynd, appeared on France 24’s Scoop on Friday, 7 February, to discuss artificial intelligence and its impact on journalism.
11/03/2025 14:00
Merkle Partners with Airship to Create Mobile Loyalty Accelerator Solution for Salesforce Marketing Cloud

Today Merkle, dentsu's leading customer experience transformation consultancy, announces a new agreement with Airship and Salesforce Marketing Cloud, creating a solution for more connected customer loyalty experiences in mobile. Now, brand marketers and product managers who are leveraging Salesforce for loyalty management can tap into Airship to help turn customers’ mobile signals into action, loyalty and value, faster. The new mobile-first loyalty framework brings the best of each platform t...